Asparaginase or pegylated-asparaginase, which could also be considered a targeted therapy, is an essential component of current ALL therapy in paediatric and AYA patients, with significantly worse outcomes reported if patients are unable to complete their intended treatment course per protocol [141]. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.